PO15

Purpose To explore the factors influencing the short-term efficacy of 125I seed implantation in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. Materials and Methods 30 patients with recurrent cervical cancer and perivascular lymph node metastasis after radiotherapy and chemotherapy, aged 28-76 years old, 16 cases of squamous cell carcinoma, 14 cases of adenocarcinoma, particle activity 0.4-0.7 mCi, peripheral dose 60-128 Gy, who were treated in our hospital from January 2006 to December 2018, were retrospectively analyzed, NRS was used to evaluate the improvement of pain and the occurrence of complications, single factor and multiple factor analysis were used to explore the factors affecting the efficacy, and the ROC curve was analyzed. Results All patients successfully completed the operation. The curative effect was evaluated in 6 months after the operation, including 14 cases of CR+PR and 16 cases of SD+PD. Univariate analysis: the size of lymph nodes and D90 immediately after the operation were the factors affecting the curative effect (P=0.001, 0.025). Multivariate analysis: tumor size was an independent pre-and post-factor affecting the curative effect (P=0.048). The ROC curve analysis showed that the longest diameter of lymph nodes was less than 4.85cm, and the prescription dose was greater than 76Gy, which was the best predictor of curative effect (AUC under the curve=0.853, 0.741; P=0.001, 0.025). The postoperative pain score was significantly reduced, and the difference was statistically significant (Z=-4.271, P<0.001). There was no fever, hemorrhage, bone marrow suppression, liver and kidney insufficiency, radiation skin and mucosa reaction in the follow-up of 6 months after operation Complications such as particle displacement. Conclusion 125I seed is safe and effective in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. The short-term effect is better when the tumor length is less than 4.85 cm and the prescription dose is greater than 76 Gy. The long-term effect and complications need further study. To explore the factors influencing the short-term efficacy of 125I seed implantation in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. 30 patients with recurrent cervical cancer and perivascular lymph node metastasis after radiotherapy and chemotherapy, aged 28-76 years old, 16 cases of squamous cell carcinoma, 14 cases of adenocarcinoma, particle activity 0.4-0.7 mCi, peripheral dose 60-128 Gy, who were treated in our hospital from January 2006 to December 2018, were retrospectively analyzed, NRS was used to evaluate the improvement of pain and the occurrence of complications, single factor and multiple factor analysis were used to explore the factors affecting the efficacy, and the ROC curve was analyzed. All patients successfully completed the operation. The curative effect was evaluated in 6 months after the operation, including 14 cases of CR+PR and 16 cases of SD+PD. Univariate analysis: the size of lymph nodes and D90 immediately after the operation were the factors affecting the curative effect (P=0.001, 0.025). Multivariate analysis: tumor size was an independent pre-and post-factor affecting the curative effect (P=0.048). The ROC curve analysis showed that the longest diameter of lymph nodes was less than 4.85cm, and the prescription dose was greater than 76Gy, which was the best predictor of curative effect (AUC under the curve=0.853, 0.741; P=0.001, 0.025). The postoperative pain score was significantly reduced, and the difference was statistically significant (Z=-4.271, P<0.001). There was no fever, hemorrhage, bone marrow suppression, liver and kidney insufficiency, radiation skin and mucosa reaction in the follow-up of 6 months after operation Complications such as particle displacement. 125I seed is safe and effective in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. The short-term effect is better when the tumor length is less than 4.85 cm and the prescription dose is greater than 76 Gy. The long-term effect and complications need further study.